Plant Name: Piper cubeba
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:1901617; organic hydroxy compound biosynthetic process | 1.503E-06 | 4.992E-03 | ALOX15, CYP3A4, HMGCR, SLC6A3 |
| MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 4.466E-07 | 4.992E-03 | HMGCR, MAPT, SLC6A3 |
| MF | GO:0005215; transporter activity | GO:0005330; dopamine:sodium symporter activity | 8.842E-07 | 4.992E-03 | SLC6A2, SLC6A3 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.768E-06 | 4.992E-03 | CYP1A2, CYP3A4 |
| BP | GO:0023052; signaling | GO:0051583; dopamine uptake involved in synaptic transmission | 4.417E-06 | 6.870E-03 | SLC6A2, SLC6A3 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 4.417E-06 | 6.870E-03 | CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 6.182E-06 | 8.413E-03 | CYP1A2, CYP3A4 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 4.487E-07 | 4.981E-05 | CYP1A2; ALOX15; CYP3A4 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 5.306E-06 | 2.945E-04 | CYP1A2; ALDH1A1; CYP3A4 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 3.052E-04 | 1.122E-02 | CYP1A2; ALOX15; ALDH1A1; HMGCR; CYP3A4 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 6.323E-04 | 1.122E-02 | CYP1A2; CYP3A4 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 4.470E-04 | 1.122E-02 | CYP1A2; CYP3A4 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 7.075E-04 | 1.122E-02 | CYP1A2; CYP3A4 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 6.694E-04 | 1.122E-02 | HMGCR; CYP3A4 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.654E-03 | 2.040E-02 | ALOX15; MAPK1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 8.917E-04 | 1.237E-02 | CYP1A2; CYP3A4 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 2.567E-03 | 2.772E-02 | LMNA; MAPK1 |
| hsa05034 | Alcoholism_Homo sapiens_hsa05034 | 4.155E-03 | 3.547E-02 | MAPK1; SLC6A3 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 3.670E-03 | 3.395E-02 | MAPK1; MAPT |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 5.107E-03 | 4.049E-02 | MAPK1; TSHR |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.747E-03 | 2.772E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | SLC6A2 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | SLC6A2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MAPK1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | SLC6A2 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | HMGCR |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| C00-D49: Neoplasms | Neuroendocrine cancer | C7A | SLC6A2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | SLC6A2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | SLC6A2; SLC6A2 |
| A00-B99: Certain infectious and parasitic diseases | HBV infection | B16, B18.0, B18.1 | HMGCR |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | HMGCR |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | HMGCR |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HMGCR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | SLC6A2; SLC6A2; SLC6A2; SLC6A2 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| C00-D49: Neoplasms | Multiple myeloma | C90 | HMGCR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | SLC6A2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | HMGCR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | HMGCR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | SLC6A2 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| C00-D49: Neoplasms | Cancer | C00-C96 | MAPK1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | SLC6A2; CYP3A4 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HMGCR |
| NA: NA | Cardiovascular disease | NA | HMGCR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Elevated CRP | E78.0 | HMGCR |
| K00-K95: Diseases of the digestive system | Chemotherapy or radiotherapy-induced mucositis | K12.3, R52, G89 | HMGCR |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT |
| NA: NA | Dyslipidemia | NA | HMGCR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | HMGCR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HMGCR |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| NA: NA | Hyperlipidemia | NA | HMGCR |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cancer pain | R52, G89 | SLC6A2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | SLC6A2 |
| C00-D49: Neoplasms | Neuroblastoma | C74.1, C74.9, C75.4, C75.5, D35.0, D35.5, D35.6, D44.6, D44.7 | SLC6A2 |